XML 123 R98.htm IDEA: XBRL DOCUMENT
v3.20.4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Jan. 03, 2021 | Dec. 29, 2019 | Dec. 30, 2018
Segment Reporting Information [Line Items] |  |  |
Earnings before provision for taxes on income | $ 16,497 | $ 17,328 | $ 17,999
Identifiable Assets | 174,894 | 157,728 |
Additions to Property, Plant & Equipment | 3,347 | 3,498 | 3,670
Depreciation and Amortization | 7,231 | 7,009 | 6,929
Sales to Customers | $ 82,584 | $ 82,059 | $ 81,581
Wholesaler 2 | Sales Revenue, Net |  |  |
Segment Reporting Information [Line Items] |  |  |
Concentration risk (as a percent) | 12.00% | 12.00% | 11.00%
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 43,133 | $ 42,097 | $ 41,884
Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 39,451 | 39,962 | 39,697
Consumer |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 14,053 | 13,898 | 13,853
Consumer | United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 6,362 | 5,839 | 5,761
Consumer | Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 7,691 | 8,059 | 8,092
Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 45,572 | 42,198 | 40,734
Pharmaceutical | United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 25,735 | 23,874 | 23,286
Pharmaceutical | Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 19,837 | 18,324 | 17,448
Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 22,959 | 25,963 | 26,994
Medical Devices | United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 11,036 | 12,384 | 12,837
Medical Devices | Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 11,923 | 13,579 | 14,157
Segments Total |  |  |
Segment Reporting Information [Line Items] |  |  |
Identifiable Assets | 143,091 | 132,372 |
Additions to Property, Plant & Equipment | 3,091 | 3,190 | 3,293
Depreciation and Amortization | 6,931 | 6,689 | 6,593
Corporate, Non-Segment |  |  |
Segment Reporting Information [Line Items] |  |  |
Less: Expense not allocated to segments | 945 | 835 | 1,286
Corporate, Non-Segment | General Corporate |  |  |
Segment Reporting Information [Line Items] |  |  |
Identifiable Assets | 31,803 | 25,356 |
Additions to Property, Plant & Equipment | 256 | 308 | 377
Depreciation and Amortization | 300 | 320 | 336
Operating Segments |  |  |
Segment Reporting Information [Line Items] |  |  |
Earnings before provision for taxes on income | 17,442 | 18,163 | 19,285
Sales to Customers | 82,584 | 82,059 | 81,581
Operating Segments | United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 43,133 | 42,097 | 41,884
Operating Segments | Consumer |  |  |
Segment Reporting Information [Line Items] |  |  |
Earnings before provision for taxes on income | (1,064) | 2,061 | 2,320
Identifiable Assets | 27,355 | 26,618 |
Additions to Property, Plant & Equipment | 248 | 328 | 438
Depreciation and Amortization | 785 | 765 | 688
Operating Segments | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Earnings before provision for taxes on income | 15,462 | 8,816 | 12,568
Identifiable Assets | 66,158 | 56,292 |
Additions to Property, Plant & Equipment | 863 | 950 | 1,012
Depreciation and Amortization | 4,006 | 3,910 | 3,802
Operating Segments | Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Earnings before provision for taxes on income | 3,044 | 7,286 | 4,397
Identifiable Assets | 49,578 | 49,462 |
Additions to Property, Plant & Equipment | 1,980 | 1,912 | 1,843
Depreciation and Amortization | 2,140 | 2,014 | 2,103
Immunology | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 15,055 | 13,950 | 13,120
Immunology | Pharmaceutical | United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 10,175 | 9,641 | 9,073
Immunology | Pharmaceutical | Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,880 | $ 4,309 | $ 4,047

X
- Definition Expense not allocated to segments. + References No definition available. + Details
Name: | jnj_ExpenseNotAllocatedToSegments
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=jnj_Wholesaler2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |